Sunday, November 8, 2026

GBP/EUR Bearish Momentum With A 1% Fall In The Last 10 Sessions

GBP/EUR Bearish Momentum With A 1% Fall In The Last 10 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 1.06% for the last 10 sessions. At 04:10 EST on Friday, 21 July, GBP/EUR (GBPEUR) is $1.16.

GBP/EUR's yearly highs and lows, it's 6.945% up from its 52-week low and 3.545% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.24%, a negative 0.03%, and a positive 0.26%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.28% (last week), 0.29% (last month), and 0.26% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy struggles to gain any meaningful traction, holds steady near 139.00 mark. According to FXStreet on Wednesday, 19 July, "This has been a key factor behind the recent corrective decline in the US Treasury bond yields, which keeps the USD bulls on the defensive and might cap the upside for the USD/JPY pair.", "The underlying bullish sentiment surrounding the global equity markets undermines the safe-haven Japanese Yen (JPY) and turns out to be a key factor lending some support to the USD/JPY pair. "
  • Usd/jpy price analysis: not out of the woods yet, bearish flag spotted on hourly charts. According to FXStreet on Wednesday, 19 July, "Furthermore, oscillators on the daily chart are holding deep in the negative territory and validate the negative outlook for the USD/JPY pair.", "Apart from this, a modest US Dollar (USD) uptick is seen as a key factor lending some support to the USD/JPY pair. "
  • Usd/jpy justifies risk-barometer status above 139.00, ignores softer yields, fed bias. According to FXStreet on Wednesday, 19 July, "Furthermore, fears surrounding Japan Prime Minister (PM) Fumio Kishida's cabinet reshuffle and pessimism among the big industrial houses from Tokyo weigh on the Japanese Yen (JPY) and favor the USD/JPY bulls.", "However, the US 10-year and two-year Treasury bond yields stay pressured at 3.76% and 4.74% by the press time and prod the USD/JPY bulls of late."
  • Usd/jpy is understandably recovering some lost ground – MUFG. According to FXStreet on Wednesday, 19 July, "The renewed bounce in USD/JPY was in part triggered by comments from Governor Ueda at the G20 summit in India on Tuesday. ", "But in a backdrop of improved risk appetite and soft-landing optimism, USD/JPY is understandably recovering some lost ground."
  • Usd/jpy technical analysis: the rebound to the upside lacks momentum - 19 July 2023. According to DailyForex on Wednesday, 19 July, "According to the performance on the daily chart below, the price of the USD/JPY currency pair is still in attempts to rebound upwards, and the bulls' control over the trend will strengthen if the currency pair returns to the resistance levels of 140.50 and 141.70, respectively.", "Currently, the closest levels of support for the USD/JPY are 138.45 and 137.00, respectively. "

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com